Neos Therapeutics Inc. granted Actavis Laboratories FL Inc. a license to market a generic version of its attention deficit hyperactivity disorder drug as part of a settlement agreement.

Neos had filed a patent litigation against the Teva Pharmaceutical Industries Ltd. unit after it sought U.S. Food and Drug Administration approval to introduce a generic version of Adzenys XR-ODT.

Under the settlement, Actavis Laboratories can market its generic drug starting Sept. 1, 2025, or earlier, under certain circumstances.

The agreement is subject to the approval of the Federal Trade Commission and the U.S. Department of Justice.